...
search icon
crbp-img

Corbus Pharmaceuticals Holding, Common Stock

CRBP

NAQ

$7.4

-$0.14

(-1.86%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$89.82M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
79.67K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
3.20
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.64 L
$61.9 H
$7.4

About Corbus Pharmaceuticals Holding, Common Stock

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCRBPSectorS&P500
1-Week Return0.82%-1.91%-1.87%
1-Month Return0.14%-3.82%8.93%
3-Month Return-2.25%-11.56%-2.39%
6-Month Return-58.77%-10.21%-2.41%
1-Year Return-82.12%-9.91%10.88%
3-Year Return-21.44%-0.28%46.93%
5-Year Return-96.92%31.29%94.89%
10-Year Return-93.51%75.9%177.5%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue3.94M881.71K---[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22.39,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue98.27K1.64M1.49M31.17M-[{"date":"2020-12-31","value":0.32,"profit":true},{"date":"2021-12-31","value":5.26,"profit":true},{"date":"2022-12-31","value":4.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit3.84M(757.53K)(1.49M)(31.17M)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-19.73,"profit":false},{"date":"2022-12-31","value":-38.76,"profit":false},{"date":"2023-12-31","value":-811.88,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin97.50%(85.92%)---[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-88.12,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses126.75M56.87M34.84M13.91M48.72M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":44.87,"profit":true},{"date":"2022-12-31","value":27.48,"profit":true},{"date":"2023-12-31","value":10.97,"profit":true},{"date":"2024-12-31","value":38.44,"profit":true}]
Operating Income(122.81M)(55.99M)(39.84M)(45.08M)(48.72M)[{"date":"2020-12-31","value":-12281023300,"profit":false},{"date":"2021-12-31","value":-5598902400,"profit":false},{"date":"2022-12-31","value":-3983544500,"profit":false},{"date":"2023-12-31","value":-4507730100,"profit":false},{"date":"2024-12-31","value":-4872100000,"profit":false}]
Total Non-Operating Income/Expense10.51M8.52M(4.64M)(2.38M)8.51M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":81.03,"profit":true},{"date":"2022-12-31","value":-44.17,"profit":false},{"date":"2023-12-31","value":-22.68,"profit":false},{"date":"2024-12-31","value":80.97,"profit":true}]
Pre-Tax Income(111.27M)(45.64M)(42.35M)(44.60M)(40.21M)[{"date":"2020-12-31","value":-11126938000,"profit":false},{"date":"2021-12-31","value":-4564042600,"profit":false},{"date":"2022-12-31","value":-4234690300,"profit":false},{"date":"2023-12-31","value":-4460331600,"profit":false},{"date":"2024-12-31","value":-4020900000,"profit":false}]
Income Taxes35.05K(87.84K)13.49M--[{"date":"2020-12-31","value":0.26,"profit":true},{"date":"2021-12-31","value":-0.65,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(111.30M)(45.55M)(55.83M)--[{"date":"2020-12-31","value":-11130442600,"profit":false},{"date":"2021-12-31","value":-4555258800,"profit":false},{"date":"2022-12-31","value":-5583319300,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(111.27M)(45.64M)(42.35M)(47.46M)(40.21M)[{"date":"2020-12-31","value":-11126938000,"profit":false},{"date":"2021-12-31","value":-4564042600,"profit":false},{"date":"2022-12-31","value":-4234690300,"profit":false},{"date":"2023-12-31","value":-4746097500,"profit":false},{"date":"2024-12-31","value":-4020900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(111.30M)(45.55M)(55.83M)(44.60M)(40.21M)[{"date":"2020-12-31","value":-11130442600,"profit":false},{"date":"2021-12-31","value":-4555258800,"profit":false},{"date":"2022-12-31","value":-5583319300,"profit":false},{"date":"2023-12-31","value":-4460331600,"profit":false},{"date":"2024-12-31","value":-4020900000,"profit":false}]
EPS (Diluted)(44.10)(11.70)(10.41)(10.15)(3.66)[{"date":"2020-12-31","value":-4410,"profit":false},{"date":"2021-12-31","value":-1170,"profit":false},{"date":"2022-12-31","value":-1041,"profit":false},{"date":"2023-12-31","value":-1015,"profit":false},{"date":"2024-12-31","value":-366,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CRBP
Cash Ratio 1.63
Current Ratio 11.82

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CRBP
ROA (LTM) -27.18%
ROE (LTM) -44.89%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CRBP
Debt Ratio Lower is generally better. Negative is bad. 0.09
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.91

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CRBP
Trailing PE NM
Forward PE NM
P/S (TTM) 163.32
P/B 0.73
Price/FCF NM
EV/R 8.26
EV/Ebitda 0.17
PEG NM

FAQs

What is Corbus Pharmaceuticals Holding share price today?

Corbus Pharmaceuticals Holding (CRBP) share price today is $7.4

Can Indians buy Corbus Pharmaceuticals Holding shares?

Yes, Indians can buy shares of Corbus Pharmaceuticals Holding (CRBP) on Vested. To buy Corbus Pharmaceuticals Holding from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRBP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Corbus Pharmaceuticals Holding be purchased?

Yes, you can purchase fractional shares of Corbus Pharmaceuticals Holding (CRBP) via the Vested app. You can start investing in Corbus Pharmaceuticals Holding (CRBP) with a minimum investment of $1.

How to invest in Corbus Pharmaceuticals Holding shares from India?

You can invest in shares of Corbus Pharmaceuticals Holding (CRBP) via Vested in three simple steps:

  • Click on Sign Up or Invest in CRBP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Corbus Pharmaceuticals Holding shares
What is Corbus Pharmaceuticals Holding 52-week high and low stock price?

The 52-week high price of Corbus Pharmaceuticals Holding (CRBP) is $61.9. The 52-week low price of Corbus Pharmaceuticals Holding (CRBP) is $4.64.

What is Corbus Pharmaceuticals Holding price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Corbus Pharmaceuticals Holding (CRBP) is 0.73

What is the Market Cap of Corbus Pharmaceuticals Holding?

The market capitalization of Corbus Pharmaceuticals Holding (CRBP) is $89.82M

What is Corbus Pharmaceuticals Holding’s stock symbol?

The stock symbol (or ticker) of Corbus Pharmaceuticals Holding is CRBP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top